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Abstract 
    To evaluate the effect of coupling of recombinant human serum albumin (rHSA) onto the 
surface of poly(ethylene glycol)-modified liposome (PEG liposome) on the in-vivo disposition 
characteristics of liposomal doxorubicin (DXR), the pharmacokinetics and tissue distribution of 
DXR were evaluated after intravenous administration of rHSA-modified PEG (rHSA/PEG) 
liposomal DXR into tumor-bearing rats.  rHSA/PEG liposome prepared using a 
hetero-bifunctional cross-linker, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), efficiently 
encapsulated DXR (over 95%).  rHSA/PEG liposomal DXR showed longer blood-circulating 
property than PEG liposomal DXR and the hepatic and splenic clearances of rHSA/PEG liposomal 
DXR were significantly smaller than those of PEG liposomal DXR.  It was also demonstrated that 
the disposition of DXR to the heart, one of the organs for DXR-related side-effects, was 
significantly smaller than free DXR.  Furthermore, the tumor accumulation of rHSA/PEG 
liposomal DXR was significantly larger than that of PEG liposomal DXR.  The “therapeutic 
index”, a criterion for therapeutic outcome, for rHSA/PEG liposomal DXR was significantly higher 
than PEG liposomal DXR.  These results clearly indicate that rHSA-conjugation onto the surface 
of PEG liposome would be a useful approach to increase the effectiveness and safety of PEG 
liposomal DXR.  
 
Keywords: recombinant human serum albumin (rHSA); PEG liposome; doxorubicin; tumor-bearing 
rats; passive targeting 
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1. Introduction 
Liposomes containing either monosialoganglioside GM1 (Allen et al., 1989) or polyethylene 
glycol (PEG) derivatives (Blume and Cevc, 1990; Klibanov et al., 1990; Allen et al., 1991; 
Maruyama et al., 1992; Woodle and Lasic, 1992; Yuda et al., 1996) are not readily taken up by the 
macrophages in reticuloendothelial system (RES), and hence remain in the blood circulation for a 
relatively long period of time.  Particularly, PEG-modified liposomes (PEG liposomes) have been 
utilized as a particulate carrier for anti-tumor therapy due to their long circulation time.  Generally, 
as the capillary permeability of the endothelium in newly vascularized tumors is significantly 
greater than that of normal organs, long-circulating PEG liposomes are preferentially delivered and 
accumulated into the tumors (Enhanced permeability and retention (EPR) effect), which provides a 
great opportunity for passive targeting of liposomal anticancer agents into tumor tissues (Maeda et 
al., 2000; Luigi et al., 2003). 
Doxorubicin hydrochloride (DXR) is the most commonly used anthracycline and is one of the 
most active agents in the treatment of breast cancer.  However, it sometimes causes cardiotoxicity, 
which could lead to congestive heart failure and death (Dresdale et al., 1983; Speth et al., 1988).  
One of the approaches to avoid DXR-related toxicity is to encapsulate it into appropriate drug 
carriers, which provides a change in the in-vivo distribution of DXR, resulting in reduced DXR 
levels in the heart (Abraham et al., 2005).  DXR encapsulated in PEG liposome, known as Doxil in 
the United States, has revealed an increased therapeutic efficacy and reduced cardiotoxicity 
compared to free DXR (Working and Dayan, 1996; Gabizon et al., 2003). 
In the previous study, we reported that rat serum albumin (RSA)-conjugated PEG liposomes 
showed the longer circulation time than PEG liposomes after intravenous administration into rats 
(Furumoto et al., 2007), suggesting the potential of the albumin-conjugated PEG liposomes as a 
suitable carrier for various anticancer drugs.  Albumin is one of the endogenous, non-toxic, 
non-immunogenic and relatively hydrophilic proteins in the body.  Its introduction on the surface 
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of liposomes reduced the association of serum proteins including some given serum opsonins onto 
the surface, resulting in the more prolonged circulation time of PEG liposome (Furumoto et al., 
2007).  However, since the conjugation of rat serum albumin onto PEG liposome with 
carbodiimide has to be conducted under weakly acidic condition, the pH remote loading method 
(Mayer et al., 1986; Madden et al., 1990), which can encapsulate DXR into the liposome very 
efficiently, was not available.  In the present study, we changed the method for albumin 
conjugation in order to encapsulate DXR into liposomes by utilizing the pH remote loading method.  
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) (Carlsson et al., 1978) was selected as a 
hetero-bifunctional cross-linking agent to couple recombinant human serum albumin (rHSA) onto 
PEG liposome.  This method allowed us to employ the pH remote loading of DXR into the 
liposome.  Then, the effect of rHSA-conjugation to PEG liposome was evaluated in terms of 
pharmacokinetics and biodistribution of liposomal DXR in Yoshida sarcoma (LY-80)-bearing rats. 
 
2. Materials and methods 
2.1. Materials 
Egg phosphatidylcholine (egg PC) was purchased from ASAHI KASEI Chemicals Industry Inc. 
(Tokyo, Japan).  Cholesterol (Chol), doxorubicin hydrochloride (DXR) and daunorubicin 
hydrochloride were obtained from Wako Pure Chemical Industry Inc. (Osaka, Japan).  Dioleoyl 
phosphatidylethanolamine (DOPE) and distearoylphosphatidylethanolamine-N-[methoxy poly 
(ethylene glycol)-2000] (PEG-DSPE) were purchased from NOF Inc. (Tokyo).  SPDP was 
purchased from PIERCE Inc. (Rockford, IL, USA).  rHSA was gifted from Bipha Inc. (Chitose, 
Japan).  
 
2.2. Synthesis of PDP-DOPE, as a linker of rHSA-conjugation with liposomes 
We synthesized a DOPE derivatized with terminal pyridyldithiopropionate (PDP) groups as 
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previously reported (Barbet et al., 1981; Ishimori et al., 1984).  Mixture of DOPE in chloroform 
and SPDP in methanol (SPDP:DOPE = 67.2:78 molar ratio) were stirred for 2 hr under nitrogen gas 
at room temperature after a small aliquot of triethylamine was added to the mixture.  To remove 
unreacted SPDP, the organic phase was reverse-extracted with phosphate buffered saline (PBS, pH 
7.4) three times.  After the organic solvent was evaporated, the residue was re-dissolved in 
chloroform to give a final concentration of 10 μmol PDP-DOPE/mL.  Thin layer chromatography 
(solvent; chloroform:methanol:water = 65:25:4 molar ratio) on silica gel indicated a single spot 
under UV illumination. 
 
2.3. Preparation of liposomes 
Liposomes were prepared according to the following procedures.  Lipid mixture (Egg 
PC:Chol:PEG-DSPE:PDP-DOPE = 61:30:5:4 molar ratio) was dried by rotary evaporator at 40°C.  
Two-hundred and fifty mM ammonium sulfate solution (pH 5.5) was added to the thin-film of lipids 
and the mixture was hydrated at 60°C.  The resultant suspension was extruded at least 10 times 
through polycarbonate membranes of 100 nm pore size (Whatman plc., Brentford, UK).  External 
solution was replaced with PBS (pH 8.0) by gel filtration with a Sephadex G-25 column (PD-10, 
GE Healthcare Ltd., Buckinghamshire, UK). 
DXR was encapsulated into liposome using the pH remote loading method (Bolotin et al., 
1994).  DXR was dissolved at 7 mg/mL in PBS (pH 8.0), and then, immediately mixed with 
liposomal suspension and incubated at 60°C for 1 hr.  Non-encapsulated DXR was removed with a 
PD-10 column equilibrated with PBS (pH 8.0).  The extent of DXR encapsulation was determined 
by measuring liposomal DXR amount by HPLC method as described below.  
 
2.4. Coupling of PDP-rHSA to liposomes 
SPDP in methanol was added to rHSA dissolved in PBS (SPDP:rHSA = 20:1 molar ratio) 
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under nitrogen gas and the mixture was incubated at room temperature for 30 min.  Excess of 
SPDP was then removed by Sepharose CL-6B column (Bio-Rad, Emeryville, CA) equilibrated with 
acetate buffer (pH 4.5).  PDP-rHSA was incubated with dithiothreitol (DTT) (PDP-rHSA:DTT = 
1:250 molar ratio) for 20 min at room temperature and the reaction mixture was applied to a 
Sepharose CL-6B column equilibrated with PBS (pH 8.0) to remove unreacted DTT.  The 
activated rHSA in the elution was dropped to liposomal suspensions and the mixture was left at 
least for 18 hr at room temperature under nitrogen gas with gentle stirring.  Unreacted rHSA was 
removed by Sepharose CL-6B column equilibrated with PBS (pH 8.0).  As a control, “PEG 
liposome” was also prepared by coupling cysteine instead of rHSA. 
 
2.5. Physicochemical characterization of rHSA-conjugated PEG liposomes (rHSA/PEG liposomes) 
encapsulating DXR 
The diameter of the liposomes was determined by light-scattering spectroscopy using a 
NICOMP zls-370 (Particle Sizing System, Santa Barbara, CA).  Lipid and rHSA amounts were 
estimated by using Phospholipid B test Wako and albumin test Wako (Wako Pure Chemical 
Industries, Osaka), respectively.  Each liposome sample was subjected to SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) as previously reported (Furumoto et al., 2007). 
In-vitro stability of liposome encapsulating DXR was tested as follows: DXR-encapsulated 
liposomal suspensions were incubated with the same volume of rat plasma at 37°C for 2 hr.  Then, 
the released DXR was separated by the Sepharose CL-6B column and was determined 
spectrofluorometrically (Ex = 500 nm, Em = 550 nm). 
 
2.6. Determination of the amount of serum proteins associated with liposomes 
Liposomes were incubated in rat serum (liposomal suspension:serum = 1:1, v/v) for 20 min at 
37 ºC, and subsequently bulk serum proteins were removed by Sepharose CL-4B column (Bio-Rad, 
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Emeryville, CA).  The amount of serum proteins associated with liposomes was calculated by 
subtracting the amount of rHSA coupled with liposomes from the amount of total protein quantified 
by Lowry’s method (Lowry et al., 1951). 
 
2.7. Animals 
Male Donryu rats weighing 200-280 g (Charles River Laboratories Inc., Yokohama, Japan) 
were used throughout the present study.  Rats were maintained at 23ºC and 55% of humidity with 
free access to standard rat food and water.  Our investigations were performed after approval by 
our local ethical committee at Nipro Corporation and Okayama University, and in accordance with 
Principles of Laboratory Animal Care (NIH publication #85-23). 
 
2.8. In-vivo disposition experiments 
LY-80, rat ascites sarcoma cell line was kindly provided from Cell Resource Center for 
Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, 
Japan).  Rats were subcutaneously inoculated into the thigh with 1.0 × 106 LY-80 cells in a volume 
of 0.1 mL.  Liposomal DXR or free DXR was intravenously injected at 2.0 mg/kg as DXR around 
7 days after the tumor inoculation, when the tumor grew up to about 600 mm3 in volume.  Then, 
blood samples were periodically taken from the cannulated jugular vein.  Blood samples (0.2 mL) 
were centrifuged immediately at 4,000 g for 5 min and the obtained plasma samples were kept at 
-20ºC until analysis.  Tissue distribution studies were conducted as follows.  At 3 hr after 
intravenous injection, organs (liver, spleen, heart and tumor) were excised, rinsed with PBS, and 
weighed.  All tissues were stored at -20°C until analysis. 
 
2.9. Analytical method 
DXR was extracted from plasma and tissue samples as previously reported (Bally et al., 1990; 
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Embee et al., 1993).  In brief, 0.1 mL of plasma was added to 0.9 mL of saturated ammonium 
sulfate (pH 4.0 buffered saline) with daunorubicin, an internal standard.  Subsequently, the sample 
was extracted with 2 mL of chloroform/isopropanol (1:1, v/v).  Following vigorous mixing, 1,600 
g-centrifugation and the evaporation of organic phase, the residue was re-dissolved in HPLC mobile 
phase.  In the case of tissue samples, after each tissue was homogenized with PBS (pH 7.4) (3.0 
g/mL), 1 mL of the homogenate was subjected to the same procedure used for plasma samples. 
The HPLC system was composed of LC-10AS pump, SIL-10A autosampler, RF-10A 
fluorescence detector (Shimadzu, Kyoto, Japan) set at Ex = 500 nm and Em = 550 nm.  An ODS 
column (5C18, 150 × 4.6 mm I.D, Nacalai Tesque, Inc., Kyoto) was used at room temperature.  The 
mobile phase was 1/15 M KH2PO4 : CH3CN = 75 : 25 (v/v, pH 4.16, adjusted with H3PO4), which 
was delivered at 1.0 mL/min.  The coefficient of variation (CV) for standard curves ranged from 
2.3 to 5.6 and the squared correlation coefficient was over 0.99. 
 
2.10. Pharmacokinetic analysis 
Plasma concentrations of DXR (Cp) versus time curves were analyzed by Eq. (1) using the 
non-linear least-square regression program MULTI (Yamaoka et al., 1981) 
tt eBeACp βα −− ⋅+⋅=   (1) 
The area under the plasma concentration-time curve (AUC) was calculated by Eq. (2). 
∫= t pdtCAUC
0
 (t = ∞)  (2) 
Tissue clearance (CLtissue) was calculated by Eq. (3) 
t
t
tissue AUC
XCL
0
0=  (t = 3 hr) (3) 
where tAUC0  means AUC value from 0 to time t, and 
tX 0  represents the amount of liposomes in a 
tissue at time t. 
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2.11. Statistical analysis 
    Results are expressed as the mean ± S.D.  Analysis of variance (ANOVA) was used to test the 
statistical significance of differences among groups.  Statistical significance in the difference of 
the means was evaluated by using Student’s t-test or Dunnett’s test for the single or multiple 
comparisons of experimental groups, respectively.  
 
3. Results 
Several physicochemical characteristics were evaluated for DXR-encapsulated rHSA/PEG 
liposome and PEG liposome.  The average diameters of DXR-encapsulated rHSA/PEG and PEG 
liposomes were 94.4 ± 6.4 nm and 95.5 ± 8.1 nm, respectively.  DXR encapsulation efficiencies 
were 97.4 ± 1.4 % and 95.8 ± 2.1 % for rHSA/PEG liposome and PEG liposome, respectively.  
The amount of rHSA conjugated onto the surface of PEG liposome was 5.3 ± 1.6 μg/μmol total 
lipid.  SDS-PAGE analysis under non-reducing condition revealed that rHSA coupled onto the 
surface of liposome was exclusively in a monomeric form (data not shown).  The release of DXR 
from the two PEG liposomal preparations was evaluated in an in vitro study for 2 hr at 37ºC.  The 
released fraction of DXR was 2.3 ± 2.6 % or 9.3 ± 5.4 for rHSA/PEG or PEG liposome, 
respectively. 
The in-vivo disposition of DXR was evaluated after intravenous injection of free DXR, PEG 
liposomal DXR or rHSA/PEG liposomal DXR into tumor-bearing rats at a dose of 2.0 mg/kg as 
DXR.  The plasma concentration-time curves of DXR after intravenous administration of each 
preparation were shown in Fig. 1 and pharmacokinetic parameters of DXR were summarized in 
Table 1.  Figure 1 clearly shows that the injection of rHSA/PEG liposomal DXR exhibited much 
higher plasma concentrations of DXR compared with free DXR injection, and moreover 
significantly higher than the injection of PEG liposomal DXR.  AUC of DXR for rHSA/PEG 
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liposome (89.7 ± 12.9 μg·hr/mL) was significantly larger than that for PEG liposome (33.8 ± 2.8 
μg·hr/mL), but both values of AUC were extensively larger than that for free DXR (4.52 ± 0.69 
μg·hr/mL).  Total body clearance (CLtotal), distribution volume (Vd) and elimination rate constant 
(kel) of DXR for both PEG liposomal preparations were significantly smaller than those for free 
DXR.  Furthermore, rHSA/PEG liposome provided significantly smaller CLtotal and kel of DXR 
than PEG liposome.  These results clearly indicate that rHSA-conjugation prolongs the residence 
time of PEG liposomal DXR in blood circulation. 
In the in-vivo disposition study, the distribution of DXR after intravenous administration of 
each preparation was investigated for liver, spleen and heart (Fig. 2), because liver and spleen are 
main organs for liposome disposition and cardiotoxicity is a critical side-effect of DXR.  At 3 hr 
after injection, distribution of DXR into RES was larger for both PEG liposomal preparation than 
that for free DXR, but the hepatic and splenic clearances were remarkably smaller for both 
liposome preparations than that for free DXR, suggesting that rHSA/PEG and PEG liposomal 
preparations would suppress and delay the uptake of DXR into RES.  Furthermore, it was revealed 
that the hepatic and splenic clearances of DXR for rHSA/PEG liposome were significantly smaller 
than those for PEG liposome, suggesting that the affinity of rHSA/PEG liposome to these organs 
would be less than PEG liposome.  In addition, PEG liposomal preparations significantly 
suppressed the distribution of DXR into heart compared with free DXR, although there was no 
significant difference between rHSA/PEG liposome and PEG liposome (Figs. 2 and 3). 
To obtain some clue to explain the reason for the lower hepatic and splenic clearances of 
rHSA/PEG liposomal DXR than PEG liposomal DXR, we measured the amount of serum proteins 
associated onto the surface of rHSA/PEG or PEG liposomes (Fig. 3).  The result clearly 
demonstrated that the amount of associated serum proteins was significantly reduced by the 
rHSA-conjugation. 
Next, we evaluated the disposition of DXR into tumor tissue at 3 hr after intravenous 
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administration (Fig. 4).  Significantly increased tumor distribution of DXR was observed for both 
rHSA/PEG and PEG liposomal preparations compared with free DXR.  Furthermore, it should be 
noted that the amount of DXR in tumor was significantly larger for rHSA/PEG liposome than PEG 
liposome, demonstrating the usefulness of rHSA-conjugation onto PEG liposome for the better 
DXR delivery into tumor tissues. 
The therapeutic outcome of DXR would be evaluated by the balance between its anti-tumor 
effect and side-effect.  Therefore, as a criterion for therapeutic outcome, the therapeutic index, 
tumor to heart ratio of DXR amount, was calculated for both PEG liposomal preparations and free 
DXR (Fig. 4).  The therapeutic index of rHSA/PEG liposomal DXR was the largest among the 
three preparations, although PEG liposomal DXR was also significantly better than free DXR.  
This result clearly demonstrates that rHSA/PEG liposomal DXR would provide better EPR effect 
for tumor tissues than PEG liposomal DXR. 
 
4. Discussion 
Long-circulating particles are promising carriers for passive targeting of drugs into tumors or 
inflamed tissues, where the integrity of the endothelial barrier is perturbed, via EPR effect (Gabizon 
and Papahadjopoulos, 1992; Jang et al., 2003).  In this study, we tried to evaluate the 
pharmacokinetics and biodistribution of DXR encapsulated into rHSA-conjugated PEG liposome in 
tumor-bearing rats. 
Several factors such as particle size, charge and lipid composition of liposome have been 
reported to influence the in-vivo fate of liposomes after intravenous administration in rats (Gabizon 
et al., 1993; Harashima et al., 2002).  Among them, the size of liposome is one of the most 
important factors to influence the EPR effect-driven tumor disposition and the liposomes with the 
diameter of less than 150 nm are reported to be suitable for the efficient delivery (Harashima and 
Kiwada, 1996; Drummond et al., 1999; Takeuchi et al., 2001).  Therefore, we decided to prepare 
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liposomes with a diameter of 100 nm. 
In our previous study, we clearly demonstrated that RSA-conjugated PEG liposome (RSA/PEG 
liposome), prepared by using carbodiimide, prolonged the blood circulation time of PEG liposome 
after intravenous administration in rats (Furumoto et al., 2007).  Carbodiimide has been widely 
used as carboxyl- and amine-reactive crosslinker to prepare immunoliposomes (Endoh et al., 1981), 
polymer-protein conjugates (Dilgimen et al., 2001) and immunomicrospheres (MacAdam et al., 
2000).  However, the pH remote loading method is not available for DXR encapsulation into the 
albumin-conjugated PEG liposome, since carbodiimide can activate carbonyl group only at a low 
pH region, especially between 3.5 and 4.5 during the first step of reaction (Nakajima and Ikeda, 
1995).  Therefore, in the present study, we chose SPDP as the heterobifunctional-crosslinker 
(Carlsson et al., 1978) to prepare rHSA/PEG liposomes, because the coupling reaction can be 
conducted under weakly alkaline pH, which makes it possible to perform the pH remote loading 
method for encapsulating DXR into rHSA/PEG liposomes.  SPDP has been widely used for the 
preparation of disulphide-linked protein-protein conjugates (Moll and Thompson, 1994; Takeoka et 
al., 2001) and immunoliposome (Berbet et al., 1981; Ishimori et al., 1984; Schwendener et al., 
1990).  As a result, the encapsulation efficiency of DXR into rHSA/PEG liposomes or PEG 
liposomes was very high and more than 95% of DXR added was successfully encapsulated. 
In-vivo disposition studies in tumor-bearing rats revealed that the DXR encapsulation into 
rHSA/PEG liposomes or PEG liposomes dramatically changed the in-vivo disposition 
characteristics of DXR itself (Fig. 1 and Table 1).  Furthermore, rHSA-conjugation onto the 
surface of liposomes significantly prolonged the blood circulation of DXR compared with PEG 
liposomal DXR.  Taken that the in-vitro release study demonstrated that DXR was stably and 
similarly encapsulated within both liposomal preparations in the presence of plasma and that free 
DXR was immediately cleared from the blood circulation after injection (Fig. 1), the in-vivo 
disposition characteristics of rHSA/PEG liposomal DXR or PEG liposomal DXR is considered to 
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mainly represent the pharmacokinetics of each PEG liposomes themselves.  In addition, 
rHSA/PEG liposomes significantly reduced the hepatic and splenic clearances of DXR compared 
with PEG liposomes, although both PEG liposomal preparations remarkably decreased both tissue 
clearances compared with free DXR (Fig. 2B).  Although the disposition amount of DXR in the 
liver and spleen was larger for both rHSA/PEG and PEG liposomal DXR than that for free DXR, it 
would be because the distribution of DXR into and the subsequent elimination of DXR from the 
liver is delayed and prolonged for liposomal preparations, compared with free DXR.  The 
distribution of free DXR to and its subsequent elimination from the liver due to the metabolism, 
biliary excretion or efflux back to the blood stream are very fast. (Colombo et al., 1994, Working et 
al., 1996).  In the case of heart, the amount of DXR at 3 hr would reflect the accumulation of DXR 
in heart (Figs. 2 and 4), considering the very rapid elimination of free DXR from plasma (Fig. 1).  
Clearance values also confirmed that both PEG liposomal preparations significantly attenuated 
DXR distribution to heart (Fig. 2B).  As Speth et al. (1998) reported that one of the acute or 
delayed toxicities derived from DXR was cardiac arrhythmias or cardiomyopathy, respectively, the 
decrease in DXR distribution to heart would be one of the advantages rHSA/PEG liposome can 
provide. 
As described above, in-vivo disposition studies clearly indicated the longer circulation of 
rHSA/PEG liposomal DXR and lower values of tissue clearances for liver and spleen than PEG 
liposomal DXR.  The serum proteins associated onto the surface of liposomes systematically 
administered have been suggested to be one of the most important factors to determine their in-vivo 
fate (Drummond et al., 1999; Luigi et al., 2003).  Chonn et al. (1992) reported that the amount of 
serum proteins associated on the liposomes used was inversely related to their circulation half-lives.  
Our present findings also revealed that less amount of serum proteins was associated on rHSA/PEG 
liposomes than PEG liposomes (Fig. 3).  Since the recognition of surface-associated serum 
opsonins by their corresponding receptors is mainly a trigger for the receptor-mediated hepatic 
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uptake of liposomes, it is considered that the rHSA-conjugation on PEG liposome suppressed the 
association of serum proteins including some serum opsonins.  Western blotting will be useful to 
address the possible less-association of typical serum opsonins on rHSA/PEG liposome and will be 
the subject of our further study.   
The movement of liposomes into the tumor interstitium is principally via extravasation through 
the discontinuous endothelium of the tumor microvasculature (Drummond et al., 1999).  Since the 
maintenance of high blood level or large AUC of particulate drug carriers is one of the driving 
forces for the efficient extravasation into tumor tissues (Drummond et al., 1999), it can be 
considered that rHSA/PEG liposomal preparation successfully improved the tumor disposition of 
DXR over PEG liposomal preparation via EPR effect (Fig. 4).  For DXR to exert the anti-tumor 
effect, DXR must be released and taken up by the surrounding tumor cells.  Although DXR is 
stably incorporated in rHSA/PEG liposomes in plasma, DXR release from the liposome 
preparations would be enhanced after liposomes are extravasated into tumor tissues, considering 
that malignant effusions significantly elevated the release of DXR from liposome preparation 
(Gabizon A.A., 1995).  Elucidation of local release profile of DXR in tumor tissues will be the 
subject for further study. 
From the viewpoint of clinical therapeutics, the balance between pharmacological and adverse 
effects is very important.  Therefore, we calculated the therapeutic index defined as the ratio of the 
amount of DXR delivered to tumor, the site of action, to the DXR amount at potential sites of 
toxicity, heart (Fig. 4).  Therapeutic index was the highest for rHSA/PEG liposomal DXR, 
suggesting that rHSA-conjugation on PEG liposome would increase the anti-tumor effect as well as 
the safety of liposomal DXR. 
In conclusion, rHSA modification on the surface of PEG liposome significantly prolonged the 
blood circulation time of PEG liposomal DXR, leading to higher DXR amount in the tumor, but 
lower level of DXR in heart after intravenous administration.  These findings are very useful to 
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optimize albumin-conjugated PEG liposome for the passive targeting of encapsulated drug and for 
the better therapeutic outcome. 
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Legends for Figures 
 
Fig. 1    Plasma concentration – time profiles of DXR after intravenous administration of 
free DXR, PEG liposomal DXR or rHSA/PEG liposomal DXR to tumor-bearing rats.  Each 
preparation was dosed at 2.0 mg/kg as DXR.  Keys; ●, rHSA/PEG liposomal DXR; ■, PEG 
liposomal DXR; ▲, free DXR.  Results are expressed as the mean ± S.D. of three experiments. 
* p<0.05; ** p<0.01, compared with PEG liposomal DXR. † p<0.05; †† p<0.01, compared with free 
DXR. 
 
Fig. 2    Tissue distribution of DXR after intravenous administration of free DXR, PEG 
liposomal DXR or rHSA/PEG liposomal DXR to tumor-bearing rats.  (A) Distributed amount 
of DXR at 3 hr after intravenous administration.  (B) Tissue clearance calculated according to 
equation (3).  Each preparation was dosed at 2.0 mg/kg as DXR.  Keys; □, free DXR; , PEG 
liposomal DXR; ■, rHSA/PEG liposomal DXR.  Results are expressed as the mean ± S.D. of 
three experiments.  * p<0.05, compared with PEG liposomal DXR in each tissue. † p<0.05; †† 
p<0.01, compared with free DXR in each tissue. 
 
Fig. 3    Amount of serum proteins associated on surface of PEG liposome and rHSA/PEG 
liposome prepared by SPDP method.  Results are expressed as the mean ± S.D. of three 
experiments.  * p< 0.05; compared with PEG liposome.  The amount of serum proteins 
associated with rHSA/PEG liposome was calculated by subtracting the amount of rHSA coupled 
with liposomes from the total protein amount measured. 
 
Fig. 4    Amounts of DXR in tumor and heart at 3 hr (left) and therapeutic index (right) of 
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free DXR, PEG liposomal DXR or rHSA/PEG liposomal DXR after intravenous 
administration to tumor-bearing rats.  Each preparation was dosed at 2.0 mg/kg as DXR.  
Therapeutic index was calculated as the tumor to heart ratio of DXR amount.  Keys; , DXR 
amount in the tumor; □, DXR amount in the heart; ■, therapeutic index of each formulation.  
Results are expressed as the mean ± S.D. of three experiments.  * p< 0.05, compared with PEG 
liposomal DXR.  † p<0.05, compared with free DXR. 
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Table 1    Pharmacokinetic parameters of DXR after intravenous administration of free 
DXR, PEG liposomal DXR or rHSA/PEG liposomal DXR to tumor-bearing rats 
 
 AUC (μg·hr/mL) CLtotal (mL/hr) Vd (mL) kel (hr-1) 
Free DXR 4.52 ± 0.69 131.0 ± 16.1 27.8 ± 5.5 4.86 ± 1.5 
PEG liposomal 
DXR 33.8 ± 2.8
†† 17.9 ± 1.0†† 19.5 ± 4.4† 0.95 ± 0.17†† 
rHSA/PEG 
liposomal DXR 89.7 ± 12.9
*,†† 7.0 ± 1.2*,†† 14.9 ± 0.9† 0.47 ± 0.08*,† 
Each preparation was dosed at 2.0 mg/kg as DXR.  AUC, area under the plasma-concentration 
time curve; CLtotal, total clearance; Vd, apparent distribution volume; and kel, elimination rate 
constant, were calculated based on two-compartment model.  Results are expressed as the mean ± 
S.D. of three experiments.  * p<0.05, compared with PEG liposomal DXR.  † p<0.05; †† p<0.01, 
compared with free DXR. 
 
